Navigation Links
Hana Biosciences Presents Data On Two Programs At the American,Society of Clinical Oncology Annual Meeting

* Preclinical study evaluating a clinically relevant model of normal human skin found that Menadione was the only agent capable of abrogating the cytotoxic effect of erlotinib * Phase I single agent Marqibo(r) showed OPTISOME(tm) agent was generally well tolerated in metastatic melanoma patients with an adverse event profile similar to conventional vincristine

SOUTH SAN FRANCISCO, Calif., June 4, 2007 (PRIME NEWSWIRE) -- Hana Biosciences (Nasdaq:HNAB), a biopharmaceutical company focused on advancing cancer care, today announced the presentation of data for Menadione and Marqibo(r) (vincristine sulfate injection, OPTISOME(tm)) at the 43rd Annual American Society of Clinical Oncology (ASCO) Annual Meeting.

"We are pleased to have the opportunity to share data regarding our emerging anti-cancer compounds at ASCO this year. Dr. Perez-Soler presented promising preclinical data showing that Menadione may be a useful topical agent in the treatment of the rash associated with EGFR inhibitors," stated Steven R. Deitcher, M.D., Hana Bioscience's Executive Vice President of Development and Chief Medical Officer. "Marqibo again showed that it is an active drug in another difficult-to-treat histology, namely metastatic melanoma. We are looking forward to further development of Menadione, Marqibo, and the other promising drug candidates in our pipeline."

Menadione is a topical agent being developed by Hana to treat skin rashes associated with use of Epidermal Growth Factor Receptor (EGFR) inhibitors. Skin toxicity is one of the most common side effects of EGFRs and is observed with the three approved agents of this class: cetuximab (Erbitux(r); Bristol-Myers Squibb/Imclone), panitumumab (Vectibix(r); Amgen), and erlotinib (Tarceva(r); Genentech/OSI). A preclinical study evaluating a clinically relevant model of normal human skin found that Menadione was the only agent capable of abrogating the cytotoxic
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Neurocrine Biosciences Announces New Research Studies Presented at APSS Reveal Significant Under-Diagnosis of Insomnia
2. Lux Biosciences Investigational Therapy for Uveitis, LX211, is Subject of Two Presentations at Key Ophthalmology Meeting, ARVO 2007
3. Hana Biosciences Announces Data to be Presented On Talvesta (Talotrexin) for Injection at The American Association for Cancer Research Annual Meeting
4. Ace Biosciences, Ace393, the Worlds First Commercial Vaccine for Travellers Diarrhoea Caused by Campylobacter Successfully Completes Phase I Clinical Trials
5. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
6. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
7. Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Quadramet at International Myeloma Workshop
8. SemBioSys Presents Positive Insulin Data at the American Diabetes Association Conference
9. Tranzyme Pharma Presents Initial Phase IIa Data for its Novel Ghrelin Agonist, TZP-101, in Patients with Diabetic Gastroparesis
10. Novagali Pharma Presents at AACO the Results of its Pivotal Phase III Clinical Trial of Vekacia in Children Suffering From Vernal Keratoconjunctivitis
11. BioLife Solutions Presents Data on CryoStor at International Society for Cellular Therapy Annual Meeting
Post Your Comments:
(Date:10/25/2014)... 2014 In conjunction with DURECT Corporation,s (Nasdaq: ... press release, you are invited to listen to the ... internet on Monday, November 3, 2014 at 4:30 pm ... live audio webcast of the presentation will be available ... clicking "Investor Relations."  If you are unable to participate ...
(Date:10/25/2014)... 24, 2014 Best Practices designed the ... with a forum for sharing insights about the ... a mechanism for creating and sharing solutions through ... findings from the Medical Affairs Consortium survey. ... for the first roundtable of the 2014-2015 Medical ...
(Date:10/22/2014)... 2014  Cephasonics, a technology-innovation leader with a game-changing ... (cQuest Ultrasound Box™-1), the first product in a new ... by Cephasonics for purchase by companies to rebrand with ... be showcasing the cQUB-1 for the first time at ... Chongqing, China from October 23 to ...
Breaking Medicine Technology:DURECT Corporation Invites You to Join its Third Quarter 2014 Earnings Conference Call 2Strong Participation in Best Practices' Medical Affairs Consortium Survey 2Cephasonics Launches the cQUB-1, First Product in New Family of cQUB White-Label Ultrasound Systems Targeted at Medical Applications 2Cephasonics Launches the cQUB-1, First Product in New Family of cQUB White-Label Ultrasound Systems Targeted at Medical Applications 3
... SUPERIOR, Colo., Jan. 10, 2011 Key Equipment ... finance companies and an affiliate of KeyCorp (NYSE: ... entered into an exclusive, long term, program agreement with ... America is the U.S. distributor of Hitachi Medical Corporation,s ...
... Jan. 8, 2011 - Bayer HealthCare Pharmaceuticals has become aware ... pads, swabs and swabsticks manufactured by the Triad Group and ... safety, Bayer wants to ensure that U.S. patients and physicians ... The recall of the Triad Group alcohol ...
Cached Medicine Technology:Key Equipment Finance Enters Long-Term Program Agreement With Hitachi Medical Systems America 2Key Equipment Finance Enters Long-Term Program Agreement With Hitachi Medical Systems America 3Important Information for Betaseron® (interferon beta 1-b) Consumers Regarding Triad Group's Alcohol Prep Products 2Important Information for Betaseron® (interferon beta 1-b) Consumers Regarding Triad Group's Alcohol Prep Products 3
(Date:10/25/2014)... The proposed consolidation of all federally-filed ... December, when the U.S. Judicial Panel on Multidistrict Litigation ... Hearing Session Order issued by the Panel on October ... on December 4, 2014, in Charleston, South Carolina. The ... Xarelto Products Liability Litigation, No. 2592) , “Our Firm ...
(Date:10/25/2014)... (PRWEB) October 25, 2014 TASC ... medical and other benefits account management services, announces ... help employers save on taxes, reduce administrative workload, ... provide tax savings and the efficient handling of ... the Suite that best meets their goals and ...
(Date:10/25/2014)... 2014 The federal judge overseeing ... ) filed against Boston Scientific Corp. in the ... Southern District of West Virginia has denied a ... in a group of cases filed on behalf ... October 21st, U.S. District Judge Joseph R. Goodwin ...
(Date:10/25/2014)... Not getting the right amount of sleep might raise ... Those who sleep less or more than the ... more prone to developing the chronic condition, which causes ... concluded that duration and quality of sleep are key ... diseases. "Both short and long durations of sleep ...
(Date:10/25/2014)... -- October,s shorter, darker days can trigger a type ... an expert. People affected by seasonal affective ... motivation and even have trouble getting out of bed. ... Dr. Angelos Halaris, a professor in the department of ... School of Medicine. "Seasonal affective disorder should not ...
Breaking Medicine News(10 mins):Health News:Xarelto Lawsuit News: JPML to Hear Oral Arguments on Proposed Xarelto Multidistrict Litigation at December Hearing, Bernstein Liebhard LLP Reports 2Health News:Xarelto Lawsuit News: JPML to Hear Oral Arguments on Proposed Xarelto Multidistrict Litigation at December Hearing, Bernstein Liebhard LLP Reports 3Health News:TASC’s New Suites Offer Tax Savings and Protection 2Health News:Transvaginal Mesh Lawsuits Move Forward, As Federal Judge Denies Motion for Summary Judgment on Punitive Damages in Florida Cases, Bernstein Liebhard LLP Reports 2Health News:Transvaginal Mesh Lawsuits Move Forward, As Federal Judge Denies Motion for Summary Judgment on Punitive Damages in Florida Cases, Bernstein Liebhard LLP Reports 3Health News:Transvaginal Mesh Lawsuits Move Forward, As Federal Judge Denies Motion for Summary Judgment on Punitive Damages in Florida Cases, Bernstein Liebhard LLP Reports 4Health News:Sleep Duration Linked to Ulcerative Colitis Risk in Study 2Health News:Dark Days Here for Folks With Seasonal Depression 2
... Organization (NGO), sent over $3,000,000 of vitally needed medical supplies to ... ... -- In a continent often defined by man-made conflicts and natural ... success stories. Among the 53 countries in Africa there ...
... used as traditional remedies for hundreds of years. Among ... in treatment of hepatitis, inflammation, osteomyelitis and gynecological diseases ... barbata have growth inhibitory effects on a number ... of lung, breast and digestive system cancer, hepatoma, and ...
... Scantek Medical, Inc. (Pink Sheets: SKML)("Scantek") announced ... voluntary petition in the United States Bankruptcy Court pursuant ... States Code. Scantek also announced today that it ... Sensor product ("BreastCare") to a medical equipment supplier for ...
... genes initially appeared to be statistically significantly associated with ... individual studies are pooled, however, few DNA repair gene ... to a field synopsis published in the December 30 ... Cancer Institute. , Because DNA damage is associated ...
... didn,t halt women,s risk of developing disease , , TUESDAY, ... the supposed cancer-fighting powers of vitamins C and E, ... don,t prevent the disease in women. , And another ... new study found. , , "Simply taking antioxidant supplements ...
... Boston resident Barbara Gilchrest, MD, a member of ... and professor and chairman-emeritus of the Department of Dermatology ... recently named one of America,s Top Doctors by Castle ... recognized by consumers seeking high-quality medical care, is a ...
Cached Medicine News:Health News:Good News in Africa: Beyond the headlines 2Health News:Scantek Medical Files for Chapter 11 Voluntary Bankruptcy and Receives Orders for the Sale of BreastCare(TM) 2Health News:Few DNA repair genes maintain association with cancer in field synopsis 2Health News:Vitamins Fail to Prevent Cancer: Study 2Health News:Vitamins Fail to Prevent Cancer: Study 3Health News:BMC, Boston University School of Medicine dermatologist named one of America's Top Doctors 2
... The Cryostage freezing stage is a refrigerated ... object holder, primarily for use with the 8000 ... other sledge microtomes. ,The refrigerated stage gives a ... the surface is ridged to provide good adhesion ...
... work, it is necessary to cool a specimen ... be fitted to most microtomes and will permit ... depending on conditions. The equipment consists of a ... stage is best suited for operation with a ...
... Freezing Stages fit easily onto most microtomes. ... need only the AC supply and a trickle ... starts immediately and can be maintained indefinitely. ... temperatures can be set for different kinds of ...
... MNL 4404 & 4405 series Freezing Stages ... devices have no moving parts and need only ... water for operation. Freezing starts immediately ... is adjustable so that optimum cutting temperatures can ...
Medicine Products: